Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia.

Abstract

Oral treatment of cholesterol-fed rabbits with the PGI2 mimetic cicaprost largely reduces hypercholesterolemia-induced platelet and neutrophil hyperreactivity. In addition, cicaprost prevents atherosclerosis-induced platelet desensitization for PGI2. These effects persist after cicaprost treatment is withdrawn. Since platelets and leukocytes are supposed to contribute to atherogenesis, this suggests a favourable effect of long-term oral PGI2 substitution in hypercholesterolemia.

• Authors: T Hohlfeld, A Weber, K Schrör
• Journal: Agents and actions. Supplements (Agents Actions Suppl) Vol. 37 Pg. 289-96 ( 1992) ISSN: 0379-0363 [Print] Switzerland
• PMID: 1632303 (Publication Type: Journal Article)

Chemical References

• Platelet Aggregation Inhibitors
• Adenosine Diphosphate
• Collagen
• Cholesterol
• Epoprostenol
• cicaprost

Topics

• Adenosine Diphosphate (pharmacology)
• Administration, Oral
• Animals
• Cholesterol (blood)
• Collagen (pharmacology)
• Epoprostenol (administration & dosage, analogs & derivatives, pharmacology)
• Hypercholesterolemia (blood)
• Lymphocyte Activation (drug effects)
• Male
• Neutrophils (drug effects)
• Platelet Activation (drug effects)
• Platelet Aggregation (drug effects)
• Platelet Aggregation Inhibitors (pharmacology)
• Rabbits